Research To Practice | Oncology Videos

Featuring perspectives from Dr Yelena Janjigian, Prof Florian Lordick and Dr Zev Wainberg, moderated by Dr Samuel Klempner, including the following topics: • Optimizing the Selection of Therapy for Newly Diagnosed Advanced Gastric or Gastroesophageal Junction (GEJ) Cancer — Dr Klempner o Introduction (0:00) o Case: A man in his mid 50s with HER2-negative gastroesophageal adenocarcinoma (PD-L1 100%) — Victoria Giffi, MD (1:15) o Cases: A woman in her early 80s with a history of Stage 0 chronic lymphocytic leukemia, now with unresectable gastric adenocarcinoma, develops Coombs-positive hemolytic anemia after 2 cycles of FOLFOX and nivolumab and a man in his early 60s with localized adenocarcinoma of the GEJ receives the CROSS regimen but is found at surgery to have metastatic disease and tumor NGS demonstrates an ARID1A mutation — Matthew R Strickland, MD and Priya Rudolph, MD, PhD (8:05) o Faculty presentation: Dr Klempner (14:05) • Current Considerations in the Treatment of HER2-Positive Advanced Gastric/GEJ Adenocarcinoma — Dr Janjigian o Case: A woman in her early 30s with newly diagnosed metastatic HER2-amplified signet cell gastric adenocarcinoma — Farshid Dayyani, MD, PhD (22:36) o Cases: A man in his mid 80s with newly diagnosed HER2-positive gastroesophageal cancer metastatic to the liver and lung, tumor 3+ by IHC for HER2 with a PD-L1 of 10 and a woman in her mid 70s with HER2-positive esophageal adenocarcinoma and brain metastases after stereotactic radiosurgery — Warren S Brenner, MD and Dr Strickland (31:43) o Faculty presentation: Dr Janjigian • Selection and Sequencing of Therapy for Relapsed/Refractory Gastric/GEJ Cancer; Novel Investigational Approaches — Prof Lordick o Cases: A woman in her mid 70s with Lynch syndrome and a history of Stage III colon cancer presents with poorly differentiated GEJ carcinoma with liver and lung metastases and a man in his early 60s presents with a 70-lb weight loss and locally advanced high-grade neuroendocrine carcinoma of the distal esophagus — Namrata I Peswani, MD and Ranju Gupta, MD (46:19) o Case: A man in his early 60s with metastatic gastric adenocarcinoma (PD-L1 CPS 0) with clinical and radiographic progression of disease after 4 cycles of FOLFOX — Dr Strickland (52:31) o Faculty presentation: Prof Lordick (55:26) • Current Approaches to the Management of Esophageal Cancer — Dr Wainberg o Cases: A man in his late 50s with dysphagia, weight loss and a lower esophageal adenocarcinoma (T3N3) and a man in his mid 70s with dysphagia is found to have a lower esophageal adenocarcinoma with regional adenopathy and pulmonary nodules (CPS 40 by SP263) — Gurveen Kaur, MD and Liudmila N Schafer, MD (1:03:56) o Case: A woman in her early 60s with a known germline BRCA2 mutation and a history of Hodgkin lymphoma, breast and anaplastic thyroid cancers now has localized squamous cell esophageal cancer — Dr Brenner (1:11:56) o Faculty presentation: Dr Wainberg (1:17:49) CME information and select publications

Featuring perspectives from Dr D Ross Camidge, Dr Justin Gainor, Prof Benjamin Solomon and Prof Solange Peters, including the following topics: • Evolving Understanding and Management of Non-Small Cell Lung Cancer (NSCLC) with Targeted Mutations (0:00) • Adjuvant Therapy for Patients with NSCLC with Targetable Mutations (11:17) • Family Planning for Patients with Cancer (23:50) • Optimal Identification of ALK-Positive Metastatic NSCLC — Dr Camidge (30:33) • Selection of First-Line Treatment for ALK-Positive NSCLC — Dr Gainor (49:22) • Sequencing and Selection of Therapy for Relapsed/Refractory ALK-Positive NSCLC — Prof Peters (1:23:33) • Managing Side Effects of ALK Tyrosine Kinase Inhibitors (TKIs) — Prof Solomon (1:39:14) • Case: A woman in her early 40s with Stage IIIB ALK-positive NSCLC who received alectinib for more than 4 years — Dr Gainor (1:59:37) • Case: A woman in her mid 50s who remains in complete response with lorlatinib after 4 years — Prof Solomon (2:03:52) • Case: A woman in her early 60s with Stage IV NSCLC with ALK translocation who received lorlatinib followed by alectinib — Prof Peters (2:10:18) • Case: A woman in her late 60s with ALK-positive NSCLC who continues to receive brigatinib after discontinuation of alectinib due to concerns of drug-induced pneumonitis — Dr Camidge (2:15:44) • Case: A woman in her late 40s with NSCLC with an ALK fusion who received multiple ALK TKIs — Dr Gainor (2:21:11) • Case: A man in his early 30s with ALK-positive NSCLC and brain metastases who continues to receive lorlatinib after 6 years — Prof Solomon (2:26:33) CME information and select publications

Featuring perspectives from Dr Matthew Lunning, including the following topics: • Potential role of polatuzumab vedotin/R-CHP in therapy for previously untreated diffuse large B-cell lymphoma (DLBCL) (00:00) • Association between metabolic tumor volume and clinical outcomes with loncastuximab tesirine in the LOTIS-2 trial and axicabtagene ciloleucel in the ZUMA-7 trial (10:54) • Chimeric antigen receptor (CAR) T-cell therapies for large B-cell lymphomas: Activity, tolerability and patient selection (22:16) • Efficacy of and durable complete responses with bispecific antibodies in patients with DLBCL (36:48) • Five-year results and overall survival update from the Phase III AUGMENT study evaluating rituximab and lenalidomide (R2) versus rituximab and placebo for relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (42:44) • Activity and safety of tazemetostat in combination with (R2) in patients with R/R follicular lymphoma (FL) (44:52) • Long-term clinical outcomes with CAR T-cell therapies for patients with R/R FL (46:50) • Available data with and ongoing studies of bispecific antibodies for R/R FL (50:23) • Design and outcomes of the SHINE and TRIANGLE studies in mantle cell lymphoma (MCL); evolving role of transplantation for MCL (1:00:38) • Real-time monitoring of minimal residual disease in patients receiving acalabrutinib with (R2) for treatment-naïve MCL (1:13:29) • Assessment of durable responses after brexucabtagene autoleucel for R/R MCL in the ZUMA-2 trial (1:15:29) • High complete response rates with glofitamab for patients with heavily pretreated MCL (1:19:00) • Nivolumab with ICE (ifosfamide/carboplatin/etoposide) as first salvage therapy for patients with high-risk R/R Hodgkin lymphoma (1:21:04) • Efficacy and safety of camidanlumab tesirine in patients with R/R classical Hodgkin lymphoma (1:23:07) • Importance of brain-to-vein time in patients receiving CAR T-cell therapy (1:25:37) CME information and select publications

Featuring a slide presentation and related discussion from Dr Mrinal Gounder, including the following topics: • Efficacy and tolerability of sorafenib in patients with advanced and refractory desmoid tumors (00:00) • DESMOPAZ: Results of a Phase II trial of pazopanib versus IV methotrexate/vinblastine for progressive desmoid tumors (1:59) • Results of the pivotal Phase III DeFi trial evaluating the gamma secretase inhibitor (GSI) nirogacestat for progressing desmoid tumors (3:40) • Initial results of the Phase II/III RINGSIDE study of the GSI AL102 for the treatment of desmoid tumors (19:47) CME information and select publications

Featuring perspectives from Dr Mrinal Gounder, including the following topics: • Incidence and prevalence of desmoid tumors (00:00) • Outcomes associated with historical management paradigms for desmoid tumors (17:15) • Rationale for targeting the gamma secretase complex and Notch pathway as a therapeutic approach for desmoid tumors; mechanism of action of nirogacestat (20:56) • Key efficacy outcomes from the Phase III DeFi trial evaluating the gamma secretase inhibitor nirogacestat versus placebo for progressing desmoid tumors (30:14) • Spectrum and frequency of adverse events, including ovarian dysfunction, with nirogacestat (36:06) CME information and select publications

Featuring perspectives from Dr Komal Jhaveri, including the following topics: • Case: A premenopausal woman in her early 40s with a 5.8-cm, ER/PR-positive, HER2-negative infiltrating lobular carcinoma and microscopic sentinel node involvement — Arielle Heeke, MD (11:58) • Case: A premenopausal woman in her early 40s with a 3.1-cm ER/PR-positive, HER2-negative localized invasive ductal carcinoma (IDC) and a Recurrence Score® of 18 — Alan B Astrow, MD (14:51) • Case: A woman in her late 50s with ER/PR-positive, HER2-negative, microsatellite stable, BRCA1/2 wild-type, metastatic IDC with PALB2 mutation who receives palbociclib/letrozole and zoledronic acid — Shaachi Gupta, MD, MPH (19:37) • Case: A postmenopausal woman in her early 60s with de novo ER/PR-positive, HER2-low (IHC 1+) metastatic IDC after disease progression on abemaciclib/letrozole and alpelisib/fulvestrant — Zanetta S Lamar, MD (29:32) • Case: A premenopausal woman in her mid 30s with ER/PR-positive, HER2-negative IDC receiving neoadjuvant chemotherapy and goserelin, now with sexual dysfunction — Laila Agrawal, MD (34:48) • Case: A woman in her mid 60s with ER/PR-positive, HER2-low bone-only metastatic IDC on endocrine therapy alone since 2001, now experiencing asymptomatic disease progression (ESR1 variant, AKT1 mutation on liquid biopsy) — Philip L Brooks, MD (45:55) CME information and select publications

Featuring perspectives from Drs Farrukh Awan and Kelly Rogers, including the following topics: • Case: A woman in her early 90s with underlying chronic obstructive pulmonary disease was observed for 20 years for chronic lymphocytic leukemia (CLL) before initiating treatment with acalabrutinib and quickly develops fatigue, headache and diarrhea — Erik Rupard, MD (16:56) • Case: A frail man in his late 80s with CLL requiring treatment develops nonspecific side effects with acalabrutinib — Neil Morganstein, MD (29:44) • Case: A man in his late 80s with CLL was observed for 28 years before starting ibrutinib and then develops atrial fibrillation — Laurie Matt-Amaral, MD, MPH (35:05) • Case: A man in his mid 80s with CLL develops atrial fibrillation on ibrutinib while traveling overseas — Eric H Lee, MD, PhD (39:17) • Case: A man in his mid 60s with relapsed CLL treated with ibrutinib develops significant epistaxis and ecchymoses — Yanjun Ma, MD (49:01) • Case: A man in his early 60s with Waldenström macroglobulinemia receives ibrutinib/rituximab and develops elevated liver enzymes — Gigi Chen, MD (51:20) • Case: A woman in her late 60s with CLL experiences acalabrutinib-associated headaches — Rohit Gosain, MD (54:10) • Case: A man in his early 70s presents with relapsed mantle cell lymphoma after receiving bendamustine/rituximab on a clinical trial followed by acalabrutinib on progression — Zanetta S Lamar, MD (57:21) CME information and select publications

Featuring perspectives from Drs Tanios Bekaii-Saab, Scott Kopetz, and John Strickler and Prof Eric Van Cutsem, moderated by Dr Kristen Ciombor, including the following topics: • Integration of Therapies Targeting BRAF and HER2 in Metastatic Colorectal Cancer (mCRC) — Dr Strickler o Introduction (0:00) o Case: A man in his early 40s presenting with microsatellite-stable (MSS) rectal cancer and liver metastases — Victoria Giffi, MD (2:04) o Cases: A man in his late 70s with HER2-amplified colon cancer and extensive liver metastases and a man in his late 50s with KRAS G12S-mutant HER2-amplified colon cancer and lung metastases — Ranju Gupta, MD and Shaachi Gupta, MD, MPH (9:12) o Faculty presentation (16:39) • Optimizing the Use of Immune Checkpoint Inhibitors in the Management of mCRC — Dr Ciombor o Case: A man in his mid 50s with BRAF V600E-mutant, KRAS/NRAS wild-type metastatic colon cancer with disease progression on FOLFOXIRI/bevacizumab — Lai (Amber) Xu, MD, PhD (26:13) o Case: A man in his late 60s with localized unresectable microsatellite instability-high carcinoma of the cecum — Farshid Dayyani, MD, PhD (32:02) o Faculty presentation (41:11) • Evidence-Based Selection and Sequencing of Therapy for Patients with mCRC — Prof Van Cutsem o Case: A man in his late 70s with metastatic rectal cancer and newly diagnosed PMS2-positive Lynch syndrome — Liudmila N Schafer, MD (51:39) o Case: A man in his mid 50s with pan-RAS wild-type metastatic rectal cancer treated with FOLFOX/cetuximab — Warren S Brenner, MD (56:55) o Faculty presentation (1:03:36) • Promising Agents and Strategies for Patients with mCRC — Dr Bekaii-Saab o Case: A woman in her early 50s with KRAS and BRAF wild-type, HER2-negative T3N1 rectal cancer with liver and lung oligometastases who underwent multiple ablations and stereotactic body radiation therapy and is currently receiving FOLFIRI/panitumumab – MSS, mismatch repair-proficient, PD-L1 0% — Jennifer L Dallas, MD (1:13:13) o Case: A woman in her early 60s with metastatic KRAS G12C-mutant cancer of the sigmoid colon — Philip L Brooks, MD (1:18:43) o Faculty presentation (1:22:32) • The Changing Management Paradigm for Localized CRC — Dr Kopetz o Case: A man in his early 70s with 2 synchronous T3N0 cancers of the splenic flexure and cecum who is found to have circulating tumor DNA after resection — Dr Brenner (1:35:56) o Case: A man in his early 80s with a Stage II obstructing cancer of the right colon — Namrata I Peswani, MD (1:46:12) o Faculty presentation (1:47:58) CME information and select publications

Featuring perspectives from Dr Bob Li, including the following topics: • Evolution of targeted therapy for HER2-altered non-small cell lung cancer (NSCLC) (0:00) • Incidence and management of HER2 amplifications and mutations in NSCLC (10:45) • Role of ErbB/HER protein family biology in lung cancer (19:03) • Current and emerging roles of antibody-drug conjugates in lung cancer (33:43) • Considerations for clinical trial participation and improving access to care for patients with cancer (55:08) • Management of trastuzumab deruxtecan-associated interstitial lung disease (1:03:18) • Future of HER2-targeted therapy in lung cancer and beyond (1:14:39) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hodgkin and Non-Hodgkin Lymphomas — Faculty Presentation 2: Follicular Lymphoma and Mantle Cell Lymphoma — Dr Laurie Sehn CME information and select publications